For the quarter ending 2025-03-31.
| Income Statement | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Impairment of long-lived assets and restructuring | 3,068 | - | 578 | |
| Research and development | 2,116 | 12,268 | 13,765 | |
| General and administrative | 6,122 | 5,818 | 6,368 | |
| Total operating expenses | 11,306 | 18,086 | 20,711 | |
| Revenue | 1,864 | 2,370 | 2,688 | |
| Loss from operations | -9,442 | -15,716 | -18,023 | |
| Interest income and other expense, net | 1,078 | 1,608 | 1,823 | |
| Total other income (expense), net | 1,078 | 1,608 | 1,823 | |
| Net loss | -8,364 | -14,108 | -16,200 | |
| Net unrealized loss on available-for-sale securities | -9 | 60 | 13 | |
| Comprehensive loss | -8,373 | -14,048 | -16,187 | |
| Basic EPS | -0.14 | -0.23 | -0.27 | |
| Diluted EPS | -0.14 | -0.23 | -0.27 | |
| Basic Average Shares | 60,807,000 | 60,311,599 | 60,099,651 | |
| Diluted Average Shares | 60,807,000 | 60,311,599 | 60,099,651 | |
Kronos Bio, Inc. (KRON)
Kronos Bio, Inc. (KRON)